Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
C10AX20
|
| gptkbp:CASNumber |
1643489-24-0
|
| gptkbp:developedBy |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:evinacumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Evkeeza
|
| gptkbp:indication |
reduction of LDL cholesterol
treatment of rare genetic cholesterol disorders |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
ANGPTL3 inhibitor
|
| gptkbp:pregnancyCategory |
unknown
|
| gptkbp:PubChem_CID |
DB16355
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
dizziness nasopharyngitis infusion-related reactions |
| gptkbp:target |
gptkb:angiopoietin-like_protein_3
|
| gptkbp:UNII |
2ZB08T0Y1V
|
| gptkbp:usedFor |
gptkb:homozygous_familial_hypercholesterolemia
|
| gptkbp:bfsParent |
gptkb:Ultragenyx_Pharmaceutical
gptkb:Ultragenyx |
| gptkbp:bfsLayer |
7
|